2026/06/11 by Sophie Dunmall, Lucylynn Lizarondo, Romy Menghao Jia +3
Medicine · #Head and Neck Cancer Studies #Inflammatory mediators and NSAID effects #Tracheal and airway disorders
paper · doi:10.1017/s0022215126105039
crossref issued 2026/06/11 · crossref published 2026/06/11 · crossref published-online 2026/06/11 · openalex publication_date 2026/06/11 · crossref created 2026/06/11 · openalex created_date 2026/06/12 · crossref deposited 2026/07/30 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31
Abstract Objectives This study aimed to determine the safety of selective cyclooxygenase 2 inhibitors in tonsillectomy patients. Methods A systematic review of the literature was undertaken in August 2024 (updated March 2025) using Joanna Briggs Institute systematic review and critical appraisal methodology. Study outcomes were bleeding incidence, analgesic efficacy and adverse effects. Eligible comparators were non–cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs or placebo. Results Fifteen studies were included for meta-analysis, 14 of which were randomised control trials. The studies were overall of good quality. There was no increased risk of bleeding with selective cyclooxygenase 2 inhibitors (odds ratio = 1.27; 95 per cent confidence interval: 0.51 to 3.16; p = 0.61). They were more effective than placebo in providing analgesia (odds ratio = -1.22; 95 per cent confidence interval, -2.12 to -0.33; Z = 2.67; p = 0.007; I 2 = 84 per cent). Conclusion Selective cyclooxygenase 2 inhibitors do not cause an increase in bleeding risk for tonsillectomy patients. There is insufficient evidence to compare their safety and efficacy to non-selective non-steroidal anti-inflammatory drugs such as ibuprofen.